BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:BEAM

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/13	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2025/01/13	21 : 00	GlobeNewswire Inc.	Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts	NASDAQ:BEAM	Beam Therapeutics Inc
2025/01/07	07 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2025/01/07	07 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2025/01/03	10 : 04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/31	09 : 29	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/31	09 : 26	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/20	06 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/20	06 : 05	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/17	21 : 00	GlobeNewswire Inc.	Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/09	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/09	03 : 45	GlobeNewswire Inc.	Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/08	01 : 30	GlobeNewswire Inc.	Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/06	21 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/06	21 : 00	GlobeNewswire Inc.	Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/04	21 : 08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/12/04	21 : 00	GlobeNewswire Inc.	Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/13	06 : 01	GlobeNewswire Inc.	Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/09	06 : 10	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	23 : 06	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	23 : 00	GlobeNewswire Inc.	Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	22 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:BEAM	Beam Therapeutics Inc
2024/11/05	20 : 30	GlobeNewswire Inc.	Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs	NASDAQ:BEAM	Beam Therapeutics Inc
2024/10/29	19 : 30	GlobeNewswire Inc.	Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting	NASDAQ:BEAM	Beam Therapeutics Inc
2024/10/22	05 : 11	Edgar (US Regulatory)	Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]	NASDAQ:BEAM	Beam Therapeutics Inc
2024/10/17	05 : 44	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/10/16	00 : 37	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BEAM	Beam Therapeutics Inc
2024/10/08	06 : 00	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:BEAM	Beam Therapeutics Inc